Value of serum glycated albumin and high-sensitivity C-reactive protein levels in the prediction of presence of coronary artery disease in patients with type 2 diabetes by Pu, Li Jin et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
Cardiovascular Diabetology
Open Access Original investigation
Value of serum glycated albumin and high-sensitivity C-reactive 
protein levels in the prediction of presence of coronary artery 
disease in patients with type 2 diabetes
Li Jin Pu†, Lin Lu†, Xue Wei Xu, Rui Yan Zhang, Qi Zhang, Jian Sheng Zhang, 
Jian Hu, Zheng Kun Yang, Feng Hua Ding, Qiu Jin Chen, Sheng Lou, 
Jie Shen, Dan Hong Fang and Wei Feng Shen*
Address: Department of Cardiology, Institute of Cardiovascular Diseases, Rui Jin Hospital, Jiaotong Univerisity Medical School, Shanghai, People's 
Republic of China
Email: Li Jin Pu - Plj476@yahoo.com.cn; Lin Lu - Lulinshyzl@hotmail.com.cn; Xue Wei Xu - XXW519@sina.com.cn; 
Rui Yan Zhang - zry.2630@yahoo.com.cn; Qi Zhang - Zhangqi@yahoo.com.cn; Jian Sheng Zhang - ZJS1942@yahoo.com.cn; 
Jian Hu - hujian@medmail.com.cn; Zheng Kun Yang - yangzhenkun2002@hotmai.com; Feng Hua Ding - dingding-1976@yahoo.com.cn; 
Qiu Jin Chen - cqj2003@hotmail.com; Sheng Lou - Lousheng-123@163.com; Jie Shen - albenshen@yahoo.com.cn; 
Dan Hong Fang - fangdanhong@sohu.com; Wei Feng Shen* - rjshenweifeng@yahoo.com.cn
* Corresponding author    †Equal contributors
Abstract
Background: Coronary artery disease (CAD) is a major vascular complication of diabetes mellitus and reveals high mortality.
Up to 30% of diabetic patients with myocardial ischemia remain asymptomatic and are associated with worse prognosis
compared to non-diabetic counterpart, which warrants routine screening for CAD in diabetic population. The purpose of this
study was to evaluate the clinical value of serum glycated albumin and high-sensitivity C-reactive protein (hs-CRP) levels in
predicting the presence of CAD in patients with type 2 diabetes.
Methods: Three hundred and twenty-four patients with type 2 diabetes were divided into two groups based on presence (CAD
group, n = 241) or absence (control group, n = 83) of angiographically-documented CAD (lumen diameter narrowing ≥70%).
Serum levels of glycated albumin and hs-CRP as well as serum concentrations of glucose, lipids, creatinine, blood urea nitrogen
and uric acid were measured in both groups. Predictors of CAD were determined using multivariate logistic regression model
and receiver-operating characteristic (ROC) curves.
Results: Serum glycated albumin and hs-CRP levels were significantly increased in diabetic patients with CAD. Multivariate
regression analysis revealed that male gender, age, serum levels of glycated albumin, hs-CRP, creatinine and lipoprotein (a) were
independent predictors for CAD. Areas under the curve of glycated albumin and hs-CRP and for regression model were 0.654
(95%CI 0.579–0.730, P < 0.001), 0.721 (95%CI 0.658–0.785, P < 0.001) and 0.824 (95% CI 0.768–0.879, P < 0.001), respectively.
The optimal values of cut-off point were 18.7% (sensitivity 67.9%, specificity 60.0%) for glycated albumin and 5.2 mg/l (sensitivity
72.2%, specificity 60.0%) for hs-CRP to predict CAD. Logistic regression model was defined as: P/(1-P) = EXP(-1.5 + 1.265
gender + 0.812 age + 1.24 glycated albumin + 0.953 hs-CRP + 0.902 lipoprotein(a) + 1.918 creatinine). The optimal probability
value for predicting CAD in type 2 diabetic patients was 0.648 (sensitivity 82.3%, specificity 68.6%).
Conclusion: Serum glycated albumin and hs-CRP levels were significantly elevated in patients with type 2 diabetes and CAD.
The logistic regression model incorporating with glycated albumin, hs-CRP and other major risk factors of atherosclerosis may
be useful for screening CAD in patients with type 2 diabetes.
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Background
Coronary artery disease (CAD) is a major vascular compli-
cation in patients with type 2 diabetes. Previous studies
have shown that up to 30% of the diabetic patients with
CAD had silent ischemia and experienced poor outcome
following acute coronary events [1], indicating clinical
importance of screening asymptomatic CAD in diabetic
population. Advanced glycated end products (AGEs) have
been shown to form non-enzymatically in hyperglycemic
environment and to be implicated in diabetic vascular
complications. Recent studies indicated that AGEs-medi-
ated inflammation is closely related to atherosclerosis
process in patients with diabetes [2,3]. Glycated albumin
is a predominant glycated protein in vivo and exerts
adverse effects on vascular biological function. Determi-
nation of serum glycated albumin level provides more
information other than assessment of glycemic control in
a retrospective period [4]. Although relationship between
diabetic atherogenesis and several common risk factors
(e.g., hyperglycemia, hypertension and hyperlipidemia)
have been established [5], few clinical studies have been
made, which take glycated products into account as risk
factors to predict and evaluate diabetic vascular complica-
tions. The aim of this study was to determine the clinical
value of serum glycated albumin and high-sensitivity C-
reactive protein (hs-CRP) levels for the prediction of CAD




The study population consisted of 324 consecutive
patients with type 2 diabetes, who underwent coronary
angiography for the diagnosis and interventional treat-
ment of CAD in the Department of Cardiology and
Department of Endocrinology and Metabolic Diseases,
Rui Jin Hospital, Shanghai. The diagnosis of type 2 diabe-
tes was made according to the criteria using a fasting glu-
cose level ≥7.0 mmol/L or 2-hour postprandial glucose
level ≥11.1 mmol/L. Patients who had a clinical history of
type 2 diabetes and were receiving oral hypoglycemic or
parental insulin medications were also eligible for the
study, but those with type 1 diabetes were excluded by
measurement of serum C-peptide and insulin levels. The
protocol was approved by the hospital Ethics Committee
and written informed consent was obtained from all
patients.
Coronary angiography
Coronary arteriography was performed using standard
Judkins techniques or through radial approach. Angio-
graphic analysis was carried out by interventional cardiol-
ogists, who were blinded to the study protocol. Mild CAD
on visual interpretation was defined as lumen diameter
narrowing <50%, and significant CAD as the presence of
any luminal stenosis ≥50%. For the purpose of the study,
patients were divided into two groups based on visual
angiographic results. Control group consisted of 83
patients without any or with mild CAD, and CAD group
comprised 241 patients with ≥1 significantly affected cor-
onary artery.
Biochemical investigations
Blood samples were collected after overnight fasting and
stored at -70°C prior to analysis. Serum total cholesterol
and triglyceride levels were measured by automated enzy-
matic procedures (Hoffman-La Roche, Basel, Switzer-
land). The low-density lipoprotein cholesterol (LDL-C),
high-density lipoprotein cholesterol (HDL-C) and lipo-
protein (a) (Lp [a]) were determined after separating the
lipoprotein fractions from fresh fasting sera by sequential
ultracentrifugation. Concentration of apolipoproteins A
(apo-A) and B (apo-B) were measured by immunoturbidi-
metric methods using commercial kit (Boehringer-Man-
nheim, Mannheim, Germany). Blood urea nitrogen,
creatinine, and uric acid were assessed using standard
methods.
Serum glycated albumin level was measured with
improved bromocresol purple method using Lucica TM
glycated albumin-L assay kit (Asahi Kasei Pharma, Japan).
Its linear range was 3.2–68.1% and a maximum inter-
assay coefficient of variation (CV) was 3.0%. The hs-CRP
level was determined using a high-sensitivity ELISA kit
(Biocheck Laboratories, USA) with linear range of 0.62–
119.3 mg/L and inter-assay CV <7.5%.
Statistics
All statistical analyses were performed using SPSS for Win-
dows 13.0 (SPSS Inc., Chicago, Illinois). Data are pre-
sented as frequencies and percentages for categorical
variables and mean ± SD for continuous variables, unless
otherwise indicated. Differences between groups were
assessed using the Chi-square and unpaired t tests.
Because glycated albumin, triglycerides, hs-CRP, Lp (a),
and creatinine values were not normally distributed,
between-group differences were assessed by the Mann-
Whitney U test. Univariate analysis was performed to
determine each variable's ability in predicting CAD in
patients with type 2 diabetes. Variables found to be pre-
dictive of CAD in univariate analysis were then entered
into a multivariable model using logistic regression to
determine the power of each variable for predicting CAD
in patients with type 2 diabetes. At the last step of the
analysis, the Hosmer-Lemeshow test was use to examine
models' goodness of fit. The predictive values of glycated
albumin and hs-CRP in the logistic regression model were
calculated by constructing receiver-operating characteris-
tic (ROC) curves. A 2-tailed P value of <0.05 was consid-
ered statistically significant.Cardiovascular Diabetology 2006, 5:27 http://www.cardiab.com/content/5/1/27
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Results
Baseline clinical characteristics and biochemical 
measurements
Baseline clinical characteristics and biochemical measure-
ments in both groups are listed in Table 1. Patients in
CAD group were older and more male gender and ciga-
rette smoking than those in control group. Blood pres-
sure, serum glucose level and lipid profile were similar in
the two groups, except higher serum Lp (a) and reduced
apo-A in CAD group. Serum blood urea nitrogen and cre-
atinine levels were significantly higher in CAD group than
in control group, indicating reduced renal function in
CAD group.
Logistic regression model
Serum glycated albumin and hs-CRP levels were signifi-
cantly increased in diabetic patients with CAD than in
controls (Table 1). Multivariate regression analysis
revealed that older age, male gender, serum concentra-
tions of glycated albumin, hs-CRP, Lp (a), and creatinine
were independent risk factors for CAD development in
patients with type 2 diabetes (Tables 2 and 3). The logistic
regression model for predicting CAD in diabetes was
defined as: P/(1-P) = EXP(-1.5 + 1.265 gender + 0.812 age
+ 1.24 GA + 0.953 hs-CRP + 0.902 Lp[a] + 1.918 creati-
nine), and the probability value for each patient was then
calculated by equation: P = ey/1+ey, where y = ln [P/(1-P)].
Hosmer-Lemeshow test was used to check the models'
goodness of fit and the results demonstrated a good fit
achieved (goodness of fit: Hosmer-Lemeshow χ2 = 7.465,
d.f. = 8, P = 0.487). Nagelkerke R2 value was 0.35, suggest-
ing the model explained 35% of the variation in the
dependent variable.
Receiver-operating characteristic curves
ROC plot was calculated to test predictive value of gly-
cated albumin and hs-CRP, and the effectiveness of logis-
tic regression model was also evaluated by constructing
ROC plot. A larger area under the curve of hs-CRP was
observed compared to glycated albumin. The optimal
value of cut-off point for hs-CRP and probability value of
regression model to predict CAD in patients with type 2
diabetes were 5.2 mg/l and 0.648, respectively. When
using hs-CRP as a single predictor, 67 out of 241 diabetic
patients with CAD (27.8%) could be missed (sensitivity
72.2%, specificity 60.0%). The use of regression model
may cause 43 out of 241 CAD cases (17.7%) missed (sen-
sitivity 82.3%, specificity 68.6%). The ROC plot showed
that the optimal cut-off point of regression model for
diagnosis of CAD was 0.865, with only 6 out of 83 cases
(7.1%) without CAD being falsely recognized as CAD
(sensitivity 54.5%, specificity 92.9%) (Figure 1, Table 4).
Discussion
Diabetes has been recognized as an important risk factor
for CAD, and diabetic patients are at 2-fold increased risk
of cardiovascular mortality compared to their nondiabetic
counterparts [6]. Previous studies have demonstrated that
silent myocardial ischemia, which is mainly caused by
autonomic neural dysfunction, occurred in about 20% to
25% of diabetic patients, and the prevalence may be as
high as 60% in those at high-risk [7]. Because silent myo-
Table 1: Baseline characteristics and biochemical assessments
Variable Control group (n = 83) CAD group (n = 241) P value
Men (%) 38(45.8) 165(68.5) <0.0001
Age (yrs) 62 ± 10 66 ± 10 0.001
Cigarette smoking (%) 11(13.3) 68(28.2) 0.007
Hypertension (%) 52(62.7) 175(72.6) NS
Blood pressure
Systolic (mmHg) 138 ± 21 137 ± 20 NS
Diastolic (mmHg) 81 ± 10 79 ± 11 NS
Hyperlipidemia (%) 47(56.6) 137(56.8) NS
Cholesterol
Total cholesterol (mmol/L) 4.77 ± 1.27 4.70 ± 1.15 NS
HDL-cholesterol (mmol/L) 1.19 ± 0.30 1.13 ± 0.41 NS
LDL-cholesterol (mmol/L) 2.80 ± 0.89 2.73 ± 0.90 NS
Triglycerides(mmol/L) 2.23 ± 1.79 2.01 ± 1.19 NS
Lipoprotein-a (g/L) 0.19 ± 0.11 0.25 ± 0.19 0.025
Apo-A (g/L) 1.29 ± 0.19 1.24 ± 0.22 NS
Apo-B (g/L) 0.94 ± 0.26 0.94 ± 0.25 NS
Glucose (mmol/L) 7.03 ± 1.88 7.28 ± 2.72 NS
Blood urea nitrogen (mmol/L) 5.49 ± 1.60 6.05 ± 2.29 0.043
Creatinine (μmol/L) 74.67 ± 16.31 92.59 ± 29.22 <0.0001
Uric acid (μmol/L) 307.9 ± 76.03 314.19 ± 83.07 NS
Glycated albumin (%) 19.37 ± 4.29 21.21 ± 5.24 0.001
Hs-CRP (mg/L) 7.37 ± 8.71 25.77 ± 30.35 <0.0001Cardiovascular Diabetology 2006, 5:27 http://www.cardiab.com/content/5/1/27
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cardial ischemia is responsible for more delayed diagnosis
of CAD and poorer prognosis than anginal episodes, early
detection and routine screening of CAD with simple tool
becomes important and desirable for diabetic population
[1,6,8]. The current study indicates that several serum
biomarkers could be predictive for CAD in patients with
type 2 diabetes, among which serum levels of hs-CRP and
glycated albumin appeared to be useful in clinical prac-
tice.
Serum Lp(a) concentration is an independent risk factor 
for CAD in patients with type 2 diabetes
Numerous studies have shown that elevated serum level
of Lp (a) is an independent risk factor for CAD in nondi-
abetic subjects, but its contributions to atherosclerosis in
diabetes remains in controversy [9-12]. In the present
study, Lp (a) was found to be an independent risk factor
for CAD development in a diabetic cohort, while HDL-C,
LDL-C, total cholesterol, triglyceride, hypertension, and
cigarette smoking did not enter this model, suggesting
that these traditional risk factors were not risk factors for
CAD development in these diabetic subjects. However, we
do not believe that the impact of these risk factors can be
excluded because of their being quantitatively not differ-
ent from those in control group or within normal range,
compared to Lp(a). They may exert detrimental effects
depending on how much they become glycated and oxi-
dized, which is not easy to determine at present. Cumula-
tive evidence indicates that qualitative changes in
lipoproteins may contribute to diabetic angiopathy. Gly-
cated and/or oxidized LDL have demonstrated adverse
effects on vascular cell viability, lipid accumulation,
growth factor expression and intracellular oxidative stress
[13]. Modification of HDL in diabetes by glycation and
oxidation may ameliorate efficacy of its vasoprotective
functions [13]. In addition, majority of the diabetic
patients with CAD in our study received medication of
statins, and Lp (a) is less sensitive to statin treatment,
compared to other lipoproteins. This may partly explain
why Lp(a) level was higher and entered the model. In this
study, serum creatinine level was significantly related to
the presence of CAD, and this is consistent with previous
findings that patients with renal dysfunction had high
incidence of cardiovascular disease, particular in those
with late stage renal insufficiency [14,15].
Serum glycated albumin and hs-CRP predict CAD 
development in patients with type 2 diabetes
Glycated albumin is a kind of early-stage amadori-modi-
fied reaction products formed from Schiff's base adducts
[16], and has been implicated in the pathogenesis of dia-
betic complications [17,18]. Previous studies have dem-
Table 3: Multivariate predictors of coronary artery disease in patients with type 2 diabetes
Variable B Odds ratio 95% CI P value
Constant -1.5 0.223 <0.0001
Men 1.265 3.542 1.818–6.689 <0.0001
Age ≥ 65 Yrs 0.812 2.253 1.161–4.372 0.016
Glycated albumin ≥ 20% 1.24 3.456 1.777–6.720 <0.0001
Hs-CRP ≥ 10 (mg/L) 0.953 2.593 1.313–5.119 0.006
Lp (a) ≥ 0.22 g/L 0.902 2.464 1.249–4.858 0.009
Creatinine ≥ 100 umol/L 1.918 6.805 1.956–23.673 0.003
Table 2: Univariate predicators of coronary artery disease in patients with type 2 diabetes
Variable Odds Ratio 95% Confidence interval P Value
Men 3.573 1.64–7.81 0.001
Age ≥ 65 Yrs 2.267 1.12–4.57 0.022
Cigarette smoking 1.026 0.4–2.63 0.958
Hypertension 1.158 0.57–2.36 0.686
Hyperlipidemia 1.252 0.59–2.64 0.556
Total cholesterol 1.139 0.53–2.44 0.737
HDL-cholesterol 0.871 0.57–1.34 0.568
LDL-cholesterol 0.937 0.38–2.29 0.887
Triglycerides 1.017 0.71–1.46 0.927
Lipoprotein-a ≥ 0.22 g/L 2.057 1.03–4.09 0.04
Blood urea nitrogen 0.955 0.80–1.15 0.624
Creatinine ≥ 100 (μmol/L) 8.109 2.06–31.9 0.003
Uric acid 1 1.00–1.01 0.849
Glycated albumin ≥ 20% 3.54 1.74–7.20 <0.001
Hs-CRP ≥ 10 mg/L 2.648 1.32–5.30 0.006Cardiovascular Diabetology 2006, 5:27 http://www.cardiab.com/content/5/1/27
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onstrated that glycated albumin induces oxidative stress
in the vessel wall [19], enhances pro-inflammatory
endothelial response to S100A8/A9 [20], and promotes
proliferation and migration of vascular smooth muscle
cells [21], and thereby is associated with accelerated
atherosclerosis. The present study showed that glycated
albumin was an independent risk factor for CAD in
patients with type 2 diabetes, with odds ratio being
3.456(95% CI 1.78–6.72, P < 0.001).
Measurement of blood HbA1c level has been widely used
to evaluate glycemic control in diabetic patients. We pre-
viously observed a significant correlation between serum
glycated albumin level and HbA1c concentration (r =
0.743, P < 0.001, unpublished data). Previous studies
have further shown that serum glycated albumin level pla-
teaued several weeks in diabetic patients in whom serum
glucose levels were initially poorly controlled and then
intensive insulin management was used to rapidly bring
glucose levels under control, while serum HbA1c levels
were still falling [6]. Therefore, these results indicate that
determination of serum glycated albumin level appears to
be a useful marker for predicting the presence of diabetic
complications, and also a valuable adjunct to HbA1c
measurement in reflecting short-term glycemic control.
Table 4: Diagnostic performance of glycated albumin, hs-CRP and logistic regression model
Variable Area under curve (95% CI) P value Cut-off point Sensitivity Specificity
Glycated albumin 0.654(0.579–0.730) <0.0001 18.7% 67.9% 60%
Hs-CRP 0.721(0.658–0.785) <0.0001 5.2 mg/L 72.2% 60%
Regression model 0.824(0.768–0.879) <0.0001 0.648 82.3% 68.6%
ROC curve for glycated albumin, hs-CRP and logistic regression model for predicting coronary artery disease in patients with  type 2 diabetes Figure 1
ROC curve for glycated albumin, hs-CRP and logistic regression model for predicting coronary artery disease in patients with 
type 2 diabetes.Cardiovascular Diabetology 2006, 5:27 http://www.cardiab.com/content/5/1/27
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Atherosclerosis is a long-term and chronic inflammatory
process that is exacerbated in patients with diabetes
[22,23]. CRP has been shown to be associated with arteri-
osclerosis and acute cardiovascular events [24], and has
been widely used to stratify patients at high-risk for acute
coronary events. Researches showed that patients at inter-
mediate or high risk of CAD may benefit from measure-
ment of hs-CRP with regard to individual risk prediction
[25]. The current study revealed that serum level of hs-
CRP ≥ 10 mg/L was associated with a 2.593-fold increase
in risk of CAD in type 2 diabetes when compared with hs-
CRP level < 10 mg/L. It has been found that good glycemic
control per se did not affect nontraditional risk factors for
CAD equally despite improved serum glucose level [26],
and increased hs-CRP levels were associated with other
indicators of diabetes-related cardiovascular risk, but had
no correlation with disease duration or glucose control
[27,28]. These results indicates that serum levels of hs-
CRP reflect inflammatory status in type 2 diabetes regard-
less of glycemic control, which merits hs-CRP to be an
independent biomarker for predicting CAD. Aggressive
intervention of AGEs and inflammatory process is crucial
for preventing macrovascular complications in patients
with type 2 diabetes, and many agents have been shown
to reduce hs-CRP concentrations and to inhibit AGEs for-
mation in these patients [22,25,29].
Predictive value of logistic regression model
Another major finding of the present study was that the
use of logistic regression model incorporating with gly-
cated albumin, hs-CRP and other major independent risk
factors commonly seen in type 2 diabetes was competent
to screen and predict CAD in patients with diabetes (area
under curve: 0.824). The optimal probability value of
0.648 may be more suitable for screening CAD in this
cohort with a sensitivity of 82.3% and a specificity of
68.6%. Furthermore, the probability value 0.865 was par-
ticularly useful because of its high specificity (92.9%).
Previous study showed that positive predictive value of
ECG exercise stress test for angiographically-documented
CAD in patients with diabetes was 73% [6]. Our results
suggest that the regression mode may be as effective as
exercise stress tests for screening CAD in clinical practice
with low cost, and it could also provide useful informa-
tion regarding the evaluation of the effects of therapeutic
modalities aiming to reduce incidence of cardiovascular
events in type 2 diabetes.
Limitations
The present study has several limitations. First, this is in
fact a retrospective study and the sample size in the con-
trol group was relatively small. Further study is required to
increase sample size to ascertain the differences in
biomarkers and biochemical measurements between dia-
betic patients with CAD and controls. As follow-up of the
patients has been undergoing and therefore our logistic
regression model of CAD prediction in diabetes could be
tested by clinical data regarding patient's outcome and
disease progression. Secondly, hs-CRP was the only
inflammatory factor measured in this study. Whether
other "noxious" pro-atherosclerosis inflammatory factors,
such as interleukin-6, play a role in the development of
CAD in this cohort remains to be answered. As suggested
in some studies, a cluster of "harmful" interleukins exert
synergistic and convergent effects on cardiovascular dis-
eases and glucose metabolic alterations [30]. Determina-
tion of interleukin helps understand the mechanisms of
cardiovascular diabetology on disease progression and
thereby provides potential guidance to simultaneously
control both atherosclerosis and diabetes. Finally, the
Nagelkerke R2 value of the regression model was only
0.350, suggesting that the model only explained 35% of
variation in the dependent variable, which leaves space
for some other pro-atherosclerosis risk factors to com-
plete. Among these possible factors, soluble receptor of
AGEs and other factors associated with AGE-receptor sys-
tem may warrant further investigation.
Conclusion
Serum glycated albumin and hs-CRP levels were elevated
in diabetic patients with CAD. The logistic regression
model incorporating with glycated albumin, hs-CRP and
other major risk factors of atherosclerosis may be useful
for screening CAD in patients with type 2 diabetes.
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